Bone Biologics (BBLG) Ratios
Bone Biologics Ratios
BBLG's free cash flow for Q3 2026 was $-532.27K. For the 2026 fiscal year, BBLG's free cash flow was increased by $0.00 and operating cash flow was $-532.27K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 |
| Quick Ratio | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 |
| Cash Ratio | 12.74 | 8.80 | 3.64 | 2.96 | 66.81 |
| Solvency Ratio | -7.43 | 0.28 | 0.58 | -0.58 | -16.12 |
| Operating Cash Flow Ratio | -6.43 | -10.92 | -11.49 | -1.40 | -12.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 5.38M | $ 3.48M | $ 2.91M | $ 5.95M | $ 6.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.11 | 1.29 | 1.43 | 1.02 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -1.03 | -1.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -5.01 | -1.37 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 15.37 | 18.72 |
| Net Debt to EBITDA | 1.72 | -31.03 | -6.31 | 10.01 | 8.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 99.99% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.11% | 97.47% | 94.92% | 40.51% | 146.02% |
| Return on Assets (ROA) | -53.64% | -106.49% | -239.42% | -17.48% | -24.13% |
| Return on Equity (ROE) | -57.81% | -118.04% | -307.91% | -24.96% | -24.50% |
| Return on Capital Employed (ROCE) | -60.16% | -121.11% | -324.39% | -61.63% | -16.78% |
| Return on Invested Capital (ROIC) | -60.16% | -121.11% | -324.39% | -61.63% | -16.78% |
| Return on Tangible Assets | -53.64% | -106.49% | -239.42% | -17.48% | -24.13% |
| Earnings Yield | -182.50% | -48.06% | -125.40% | -20.64% | -1.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.29 | -2.72 | -36.32 | -74.94 | -28.57 |
| Free Cash Flow Per Share | -2.29 | -2.72 | -36.32 | -74.94 | -28.57 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -1.28 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -824987.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -157.97% | -48.21% | -133.91% | -49.58% | -1.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.55 | -2.08 | -0.80 | -4.85 | -67.73 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.32 | 2.46 | 2.46 | 1.21 | 16.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.63 | -2.07 | -0.75 | -2.02 | -88.79 |
| Price-to-Operating Cash Flow Ratio | -0.63 | -2.07 | -0.75 | -2.02 | -88.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.02 | -0.09 | 0.29 | -14.47 |
| Enterprise Value Multiple | 1.17 | 48.81 | 8.57 | 0.46 | -127.13 |
| Enterprise Value | -3.63M | 5.23M | 4.11M | -344.65K | 102.41M |
| EV to EBITDA | 1.17 | 48.81 | 8.57 | 0.46 | -127.13 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 1.35 | -1.27 | -0.43 | 0.10 | -83.36 |
| EV to Operating Cash Flow | 1.35 | -1.27 | -0.43 | 0.10 | -83.36 |
| Tangible Book Value Per Share | 4.58 | 2.30 | 11.05 | 124.95 | 152.92 |
| Shareholders’ Equity Per Share | 4.58 | 2.30 | 11.05 | 124.95 | 152.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.65 | -2.71 | -34.01 | -31.19 | -37.46 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.97 | 2.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.87 | 1.00 | 1.07 | 2.40 | 0.76 |
Currency in USD